06 December 2003
Application of recombinant activated factor VII for treatment of impaired haemostasis during liver transplantation in recipients with Wilson's disease--a report of two cases.
L Jureczko, J Trzebicki, A Zawadzki, M Pacholczyk, B Łagiewska, M Kołacz, G Szyszko, E Mayzner-ZawadzkaAnn Transplant 2002; 7(3): 52-54 :: ID: 5539
Abstract
Recombinant activated factor VII (rFVIIa, NovoSeven, Novo Nordisk A/S, Denmark) is a treatment used to prevent and arrest intra- and postoperative bleeding in patients with haemophilia A or B complicated by circulating anticoagulants (inhibitors of FVIII and FIX) and in patients without haemophilia who spontaneously develop inhibitors of FVIII, i.e. in acquired haemophilia. Patients who qualify for liver transplantation due to liver dysfunction may have varying degrees of coagulation impairment and thus carry an elevated risk of massive bleeding and have worse prognosis. The authors administered recombinant activated factor VII to two patients with coagulation abnormalities in the course of Wilson's disease during liver transplantation.
In Press
Case report
Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case SeriesAnn Transplant In Press; DOI: 10.12659/AOT.951715
Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952251
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Original article
Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...Ann Transplant In Press; DOI: 10.12659/AOT.953143
Most Viewed Current Articles
24 Aug 2021 : Review article 20,545
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 16,641
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 15,898
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 15,796
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988